PRIMAXIN

Product NDC: 0006-3516
11-digit product format: 000063516
Labeler code: 0006
Product ID: 0006-3516_356d9feb-1498-4df7-80ad-5a935b238da6
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: imipenem and cilastatin sodium
Dosage form: INJECTION, POWDER, FOR SOLUTION
Route: INTRAVENOUS
Labeler: Merck Sharp & Dohme LLC
Application: NDA050587
Marketing category: NDA
Marketing start: 1985-11-26
Substance: IMIPENEM; CILASTATIN SODIUM
Active strength: 500; 500 mg/100mL; mg/100mL
Pharmacologic classes: Carbapenems [CS], Dipeptidase Inhibitors [MoA], Penem Antibacterial [EPC], Renal Dehydropeptidase Inhibitor [EPC]
NDC exclude flag: No
Listing certified through: 2027-12-31
Current FDA listing: Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N050587-001	PRIMAXIN	CILASTATIN SODIUM; IMIPENEM	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26
N050587-002	PRIMAXIN	CILASTATIN SODIUM; IMIPENEM	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-product	TE code
N050587-002	AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 88 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	RLD / RS	Approval date	Source SHA-256
2026-10-15 13:18:30	2026-09	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER / INTRAVENOUS		RLD	1985-11-26	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL	POWDER / INTRAVENOUS		RLD	1985-11-26	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N050587-001	PRIMAXIN	EQ 250MG BASE/VIAL;250MG/VIAL	POWDER / INTRAVENOUS		RLD	1985-11-26	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N050587-002	PRIMAXIN	EQ 500MG BASE/VIAL;500MG/VIAL	POWDER / INTRAVENOUS	AP	RLD, RS	1985-11-26	`4b0b4de00fa7…`

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2026-10-15 13:18:30	2026-09	N050587-002	AP	1	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N050587-002	AP	1	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N050587-002	AP	1	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N050587-002	AP	1	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N050587-002	AP	1	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N050587-002	AP	1	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N050587-002	AP	1	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N050587-002	AP	1	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N050587-002	AP	1	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N050587-002	AP	1	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N050587-002	AP	1	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N050587-002	AP	1	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N050587-002	AP	1	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N050587-002	AP	1	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N050587-002	AP	1	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N050587-002	AP	1	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N050587-002	AP	1	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N050587-002	AP	1	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N050587-002	AP	1	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N050587-002	AP	1	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N050587-002	AP	1	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	N050587-002	AP	1	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	N050587-002	AP	1	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N050587-002	AP	1	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N050587-002	AP	1	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N050587-002	AP	1	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N050587-002	AP	1	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	N050587-002	AP	1	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N050587-002	AP	1	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N050587-002	AP	1	`ea99ee380514…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	N050587-002	AP	1	`6a51e52b5d6a…`
2024-02-18 07:12 UTC	2024-02	N050587-002	AP	1	`1c564ffb4f44…`
2023-12-20 04:57 UTC	2023-12	N050587-002	AP	1	`ea1830bbd6c7…`
2023-11-28 05:40 UTC · 2 captures of this ZIP	2023-11	N050587-002	AP	1	`a72a2bbeb626…`
2023-10-25 00:34 UTC · 2 captures of this ZIP	2023-10	N050587-002	AP	1	`9b2671bbb829…`
2023-07-15 15:27 UTC · 2 captures of this ZIP	2023-07	N050587-002	AP	1	`a67488948f0b…`
2023-06-13 01:57 UTC · 3 captures of this ZIP	2023-06	N050587-002	AP	1	`3f0d92c62455…`
2023-05-13 08:27 UTC	2023-05	N050587-002	AP	1	`053a50430f4f…`
2023-01-26 05:58 UTC	2023-01	N050587-002	AP	1	`3bdfa0b2c4d7…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	N050587-002	AP	1	`3a93d1ddd44b…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product: Yes
Brand name base: PRIMAXIN
Brand name suffix: IV
Listing expiration: 2027-12-31

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
IMIPENEM	500 mg/100mL
CILASTATIN SODIUM	500 mg/100mL

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
bd5bade3-1b69-46d8-87bd-7d2fbe32b767	Product name	1	20200603
bc64ce14-a963-4b05-9b71-737977847052	Product name	1	20191008

FDA-Initiated Inactive NDC Indexing#

Effective, Related label table
Effective	Related label
2021-09-01	These highlights do not include all the information needed to use PRIMAXIN safely and effectively. See full prescribing information for PRIMAXIN. PRIMAXIN® (imipenem and cilastatin) for Injection, for intravenous use Initial U.S. Approval: 1985
2021-09-01	These highlights do not include all the information needed to use PRIMAXIN safely and effectively. See full prescribing information for PRIMAXIN. PRIMAXIN® (imipenem and cilastatin) for Injection, for intravenous use Initial U.S. Approval: 1985
2021-09-01	These highlights do not include all the information needed to use PRIMAXIN safely and effectively. See full prescribing information for PRIMAXIN. PRIMAXIN® (imipenem and cilastatin) for Injection, for intravenous use Initial U.S. Approval: 1985
2021-07-23	These highlights do not include all the information needed to use PRIMAXIN safely and effectively. See full prescribing information for PRIMAXIN. PRIMAXIN® (imipenem and cilastatin) for Injection, for intravenous use Initial U.S. Approval: 1985
2021-07-23	These highlights do not include all the information needed to use PRIMAXIN safely and effectively. See full prescribing information for PRIMAXIN. PRIMAXIN® (imipenem and cilastatin) for Injection, for intravenous use Initial U.S. Approval: 1985
2021-07-23	These highlights do not include all the information needed to use PRIMAXIN safely and effectively. See full prescribing information for PRIMAXIN. PRIMAXIN® (imipenem and cilastatin) for Injection, for intravenous use Initial U.S. Approval: 1985

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
0006-3516-59	PRIMAXINIV	25 in 1 TRAY	INJECTION, POWDER, FOR SOLUTION	25		34
0006-3516-59	PRIMAXINIV	100 mL in 1 VIAL, SINGLE-DOSE	INJECTION, POWDER, FOR SOLUTION	100		34

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
0006-3516-59	EA - Each	0006-3516	bf067233-fe2b-40e1-87b0-3b467007db75	1	2012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
CILASTATIN SODIUM	ACTIVE INGREDIENT	5428WXZ74M	PRIMAXIN IV (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [MERCK SHARP & DOHME CORP.]	16
IMIPENEM	ACTIVE INGREDIENT	71OTZ9ZE0A	PRIMAXIN IV (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [MERCK SHARP & DOHME CORP.]	16
CILASTATIN	ACTIVE MOIETY	141A6AMN38	PRIMAXIN IV (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [MERCK SHARP & DOHME CORP.]	16
IMIPENEM ANHYDROUS	ACTIVE MOIETY	Q20IM7HE75	PRIMAXIN IV (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [MERCK SHARP & DOHME CORP.]	16
SODIUM BICARBONATE	INACTIVE INGREDIENT	8MDF5V39QO	PRIMAXIN IV (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [MERCK SHARP & DOHME CORP.]	16

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
0006-3516	PRIMAXIN IV (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [MERCK SHARP & DOHME LLC]	33	Current NDC, Legacy NDC, 2 package rows	20240713_f41d8abd-7792-4918-1b93-bd83ea01955e.zip

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
71OTZ9ZE0A	IMIPENEM	74431-23-5	IMIPENEM
5428WXZ74M	CILASTATIN SODIUM	81129-83-1	CILASTATIN SODIUM

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
1726204	imipenem / cilastatin 250 MG Injection	PSN	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726214	imipenem / cilastatin 500 MG Injection	PSN	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726207	Primaxin 250 MG Injection	PSN	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726216	Primaxin 500 MG Injection	PSN	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726207	cilastatin 250 MG / imipenem 250 MG Injection [Primaxin]	SBD	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726216	cilastatin 500 MG / imipenem 500 MG Injection [Primaxin]	SBD	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726204	cilastatin 250 MG / imipenem 250 MG Injection	SCD	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726214	cilastatin 500 MG / imipenem 500 MG Injection	SCD	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726204	cilastatin (as cilastatin sodium) 250 MG / imipenem 250 MG Injection	SY	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726214	cilastatin (as cilastatin sodium) 500 MG / imipenem 500 MG Injection	SY	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726204	imipenem 250 MG / cilastatin 250 MG Injection	SY	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726214	imipenem 500 MG / cilastatin 500 MG Injection	SY	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726207	Primaxin 250 MG Injection	SY	f41d8abd-7792-4918-1b93-bd83ea01955e	34
1726216	Primaxin 500 MG Injection	SY	f41d8abd-7792-4918-1b93-bd83ea01955e	34

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Marketing start	Marketing end	Sample	Exclude flag	Status
0006-3516-59	00006351659	25 VIAL, SINGLE-DOSE in 1 TRAY (0006-3516-59) / 100 mL in 1 VIAL, SINGLE-DOSE	1985-11-26	0000-00-00	No	No	Current